drugset / Trial / NCT07167914
A Study to Assess Safety, Tolerability and Pharmacokinetics of Transdermal SFG-02 in Healthy Participants
RandomizedSequentialDouble-blindTreatment
Summary
This Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics of a novel transdermal formulation of SFG-02 following single and repeated applications in Japanese and White healthy adult participants.
Timeline
- Start
- 2025-09-09
- Primary completion
- 2026-04-27
- Completion
- 2026-04-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SFG-02 | Unknown | — | Other |
Indications
No indication recorded.